Eliquis - Medication Template PDF

Preview

Summary

Medication Template...

Description

James Sampson 6/14/21 Student Name ___________________________________________ Date ____________________

ELIQUIS apixaban Medication Name: Generic ________________________________ Trade _________________________________ Davis Drug Guide 17th Edition 2021 anti-coagulants Drug Classification: _______________________________________ Reference: _____________________________

Complete on Patient During Clinicals 5mg PO BID 61.2 kg Route, Dosage, Frequency: _________________________________ Patient Weight __________________ Hemodialysis– 5 mg twice daily What is the recommended dosage range for this medication? ____________________________ x No ____ If not explain why_____________ Is the route and dosage within guideline norms? Yes ___

How do you know the medication is working for this client? Reduction in the risk and treatment of stroke and systemic embolism. What is the expected pharmacological action for this medication? Acts as a selective, reversible site inhibitor of factor Xa, inhibiting both free and bound factor. Does not affect platelet aggregation directly, but does inhibit thrombin-induced platelet aggregation. Decreases thrombin generation and thrombus development. For what purpose is this medication being administered? Decreases risk of stroke/systemic embolism associated with nonvalvular atrial fibrillation. Prevention of deep vein thrombosis that may lead to pulmonary embolism following knee or hip replacement surgery. Treatment of and reduction in risk of recurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE). What time of day should the medication be administered and why?

Should the medication be administered or avoided in combination with any substance(s)? Contraindications/Precautions Renal impairment, Hypersensitivity, pathological bleeding, sever hepatic impairment, prosthetic heart valves

Are there any needed Laboratory assessments associated with this medication? Yes_xx__ No _____ (A) If so, what tests should be monitored and why?

Platelet counts ( risk of hypovolemia), BUN, Creatinine ( kidney function)

6/11/21 (B) What are the lab results for this client (if applicable)? When were they last drawn? ______________ PLT- 189, BUN-29 (H), Creatinine 3.8 ( H)

Side Effects/complications: (A) Common

hypersensitivity

(B) Serious/Life-Threatening Bleeding , Anaphylaxis (C) What are the side effects experienced by the client (if applicable)? none List three (3) nursing implications/interventions for this medication. Assess for s/s of stroke. Assess for s/s of DVT. Assess for s/s of PE, bleeding or PVD List two (2) patient teaching points for this medication and the reasons for each. Inform pt that they bruise more easily on this medication. Instruct pt to notify provider immediately if they have black tarry stools on the medication List any medication interactions. Drug-Drug ↑ risk of bleeding with other anticoagulants, aspirin, clopidogrel, ticagrelor, prasugrel, fibrinolytics, NSAIDs, SNRIs, or SSRIs. Concurrent use of strong inhibitors of both the CYP3A4 and P-gp enzyme systems (including itraconazole, ketoconazole, and ritonavir ) ↑ levels and bleeding risk; may need to ↓ apixaban dose or avoid concurrent use. Inducers of the CYP3A4 enzyme system and the P-gp system including carbamazepine, phenytoin, rifampin will ↓ levels and may ↑ risk of thromboses; avoid concomitant use. Drug-Natural Products: Concurrent use St. John's wort , a strong dual inducer of the CYP3A4 and P-gp enzyme systems can ↓ levels and ↑ risk of thromboses and should be avoided....